BioCryst to Report First Quarter 2025 Financial Results on May 5
Rhea-AI Summary
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced it will release its first quarter 2025 financial results on Monday, May 5, 2025. The company will host a conference call and webcast at 8:30 a.m. ET on the same day, featuring management discussion of financial results and a corporate update.
Interested parties can access the live call by dialing 1-844-481-2942 (domestic) or 1-412-317-1866 (international). A live webcast and replay will be available in the investors section at www.biocryst.com.
Positive
- None.
Negative
- None.
News Market Reaction – BCRX
In the trading session that priced this news, BCRX gained 1.76%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on Monday, May 5, 2025.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
